The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.

OBJECTIVE Our aim was to determine the prognostic significance of the systemic-immune-inflammation index (SIII) in patients with resectable pancreatic cancer, using cancer-specific survival as the primary outcome. BACKGROUND Pancreatic cancer is associated with a dysfunctional immune system and poor prognosis. We examined the prognostic significance of the SIII in patients with resectable pancreatic ductal adenocarcinoma (PDAC) and the effects of bilirubin on this index. METHODS We retrospectively assessed all pancreatic resections performed between 2004 and 2015 at 4 tertiary referral centers to identify pathologically confirmed PDAC patients. Baseline clinicopathologic characteristics, preoperative laboratory values such as absolute neutrophil, lymphocyte, and platelet counts, C-reactive protein, albumin, bilirubin, and CA19-9 levels, and also follow-up information, were collected. The associations of the calculated inflammatory indices with outcome were both internally and externally validated. RESULTS In all, 590 patients with resectable PDAC were included. The discovery and validation cohort included 170 and 420 patients, respectively. SIII >900 [hazard ratio (HR) 2.32, 95% confidence interval (CI) 1.55-3.48], lymph node ratio (HR 3.75, 95% CI 2.08-6.76), and CA19.9 >200 kU/L (HR 1.62, 95% CI 1.07-2.46) were identified as independent predictors of cancer-specific survival. Separate model analysis confirmed that preoperative SIII contributed significantly to prognostication. However, SIII appeared to lose its prognostic significance in patients with bilirubin levels above 200 μmol/L. CONCLUSIONS SIII is an independent predictor of cancer-specific survival and recurrence in patients with resectable PDAC. SIII may lose its prognostic significance in patients with high bilirubin levels. Properly designed prospective studies are needed to further confirm this hypothesis.

[1]  S. H. van der Burg,et al.  Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. , 2017, Cytokine & growth factor reviews.

[2]  M. Hennig,et al.  Platelets subvert T cell immunity against cancer via GARP-TGFβ axis , 2017, Science Immunology.

[3]  T. Luedde,et al.  Current and future biomarkers for pancreatic adenocarcinoma , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[4]  G. Gravante,et al.  A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma , 2017, Annals of the Royal College of Surgeons of England.

[5]  N. Agarwal,et al.  Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma , 2017, BMC Urology.

[6]  R. Andersson,et al.  Immune checkpoint therapy for pancreatic cancer , 2016, World journal of gastroenterology.

[7]  L. Wood,et al.  Pancreatic cancer , 2016, The Lancet.

[8]  Ji Li,et al.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance , 2016, Journal of Cancer Research and Clinical Oncology.

[9]  C. Gong,et al.  Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study , 2016, BMC Cancer.

[10]  A. Awada,et al.  Learning from the "tsunami" of immune checkpoint inhibitors in 2015. , 2016, Critical reviews in oncology/hematology.

[11]  A. Zwinderman,et al.  Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial , 2016, Trials.

[12]  N. Ferrara,et al.  The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis , 2016, Cancer Immunology Research.

[13]  H. Eguchi,et al.  Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer. , 2016, Oncology letters.

[14]  H. Imaoka,et al.  Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study , 2016, Pancreas.

[15]  R. Peracaula,et al.  Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology , 2016, PloS one.

[16]  E. Uribe-Querol,et al.  Neutrophils in Cancer: Two Sides of the Same Coin , 2015, Journal of immunology research.

[17]  A. Krasinskas,et al.  Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging , 2015, Annals of Surgical Oncology.

[18]  K. Yanaga,et al.  Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. , 2015, Surgery.

[19]  P. Marchetti,et al.  Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients , 2015, British Journal of Cancer.

[20]  H. Deng,et al.  Interaction between circulating cancer cells and platelets: clinical implication. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[21]  S. Chari,et al.  A preoperative serum signature of CEA+/CA125+/CA19‐9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer , 2015, International journal of cancer.

[22]  Q. Nunes,et al.  Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[23]  W. Guo,et al.  Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma , 2014, Clinical Cancer Research.

[24]  A. Parikh,et al.  Value of Intraoperative Neck Margin Analysis During Whipple for Pancreatic Adenocarcinoma: A Multicenter Analysis of 1399 Patients , 2014, Annals of surgery.

[25]  T. Strom,et al.  Worse Overall Survival With Preoperative Biliary Drainage in Resectable Pancreatic Cancer Patients , 2014 .

[26]  S. Sleijfer,et al.  Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. , 2014, Cancer treatment reviews.

[27]  Robert Grützmann,et al.  Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. , 2013, International journal of surgery.

[28]  J. Werner,et al.  CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy , 2013, Annals of Surgical Oncology.

[29]  A. Castells,et al.  Molecular markers in pancreatic cancer diagnosis. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[30]  T. Kawano,et al.  Correlation Between the Pretherapeutic Neutrophil to Lymphocyte Ratio and the Pathologic Response to Neoadjuvant Chemotherapy in Patients With Advanced Esophageal Cancer , 2012, World Journal of Surgery.

[31]  D. Gouma,et al.  Predicting Distant Metastasis in Patients With Suspected Pancreatic and Periampullary Tumors for Selective Use of Staging Laparoscopy , 2011, World Journal of Surgery.

[32]  M. Pencina,et al.  On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data , 2011, Statistics in medicine.

[33]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[34]  Laurie J. Gay,et al.  Contribution of platelets to tumour metastasis , 2011, Nature Reviews Cancer.

[35]  D. Gouma,et al.  Therapeutic Delay and Survival After Surgery for Cancer of the Pancreatic Head With or Without Preoperative Biliary Drainage , 2010, Annals of surgery.

[36]  Nabil Wasif,et al.  Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We Include Grade in AJCC Staging? , 2010, Annals of Surgical Oncology.

[37]  C. Roland,et al.  Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts , 2010, Experimental biology and medicine.

[38]  J. Blay,et al.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. , 2009, Cancer research.

[39]  M. Cynader,et al.  Bilirubin Possesses Powerful Immunomodulatory Activity and Suppresses Experimental Autoimmune Encephalomyelitis1 , 2008, The Journal of Immunology.

[40]  H. Friess,et al.  Surgery for Recurrent Pancreatic Ductal Adenocarcinoma , 2007, Annals of surgery.

[41]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[42]  M. Shoup,et al.  Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. , 2005, American journal of surgery.

[43]  R. Carter,et al.  Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas , 2004, British Journal of Cancer.

[44]  C. Scott-Conner,et al.  The pathophysiology of biliary obstruction and its effect on phagocytic and immune function. , 1994, The Journal of surgical research.

[45]  Meyer Saklad,et al.  GRADING OF PATIENTS FOR SURGICAL PROCEDURES , 1941 .

[46]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[47]  D. McMillan,et al.  Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. , 2010, Future oncology.

[48]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[49]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .